Compare Gilead Sciences, Inc. (GILD) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Carparts.Com Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Carparts.Com Inc trades at $8.59 (market cap $67.00M). The key difference: Gilead Sciences, Inc. is far larger — about 2717.8× Carparts.Com Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Carparts.Com Inc for 45 Days on average.
| GILD | PRTS | |
|---|---|---|
Market Cap | $182.09B | $67.00M |
Volume | 4,960,247 | 50,584 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $10.00 |
52-Week Low | $116.74 | $3.88 |
Typical Hold Time | 111 Days | 45 Days |
Enterprise Value | $205.15B | $79.96M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
CarParts.com (PRTS) trades at $8.59, down 0.23% with a bullish technical outlook. The company shows improving quarterly earnings beats but faces fundamental challenges with negative profitability metrics. Recent news highlights the company's focus on leveraging proprietary data as a competitive advantage. Technical indicators show strong moving average support while oscillators remain neutral.
The stock presents a mixed picture with strong analyst support (60% buy ratings) but persistent negative earnings. Investment opportunity lies in continued operational improvements and data-driven strategy execution, while risks include sustained negative cash flow and competitive pressures in the auto parts e-commerce sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
